Phase II Multicenter Study of Arsenic Trioxide in Patients With Myelodysplastic Syndromes
- 1 June 2006
- journal article
- research article
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 24 (16) , 2456-2464
Abstract
Purpose: To evaluate the efficacy and safety of arsenic trioxide monotherapy in patients with myelodysplastic syndromes (MDS). Patients and Methods: Patients received arsenic trioxide (0.25 mg/kg/d) on 5 consecutive days per week for 2 weeks, followed by 2 weeks’ rest (one cycle). Two patient cohorts were established according to International Prognostic Scoring System risk category: lower-risk (low or intermediate-1) or higher-risk MDS (intermediate-2 or high). For lower-risk MDS, hematologic improvement (HI) was the primary response end point. For higher-risk MDS, additional end points included complete or partial remission. Based on the expected time to response, patients receiving two or more cycles were prospectively evaluated. Results: Hematologic adverse events included neutropenia, thrombocytopenia, and febrile neutropenia. Two patients died during the study due to treatment-related toxicities. Most common grade 3/4 nonhematologic events were pneumonia, fatigue, hemorrhage, pain, and dyspnea. Among patients who received one or more doses (n = 70) or completed two or more cycles (n = 51), the HI rates were 34% and 39% in lower-risk patients, and 6% and 9% in higher-risk patients, respectively; the overall major HI rates were 20% and 22%. One higher-risk patient achieved a complete remission (3%). Major HIs were observed in all hematologic lineages; erythroid responses were the most common. Transfusion independence or reduction by ≥ 50% occurred in 33% of patients dependent on RBC transfusions. The overall median duration of HI was 6.8 months (range, 2 to 40 months). Conclusion: Arsenic trioxide monotherapy has moderate activity against MDS, with a manageable adverse effect profile. The further study of arsenic trioxide in MDS, particularly in combination with other agents, is warranted.Keywords
This publication has 27 references indexed in Scilit:
- Arsenic Trioxide in Patients With Myelodysplastic Syndromes: A Phase II Multicenter StudyJournal of Clinical Oncology, 2006
- FDA Drug Approval Summary: Azacitidine (5-azacytidine, Vidaza™) for Injectable SuspensionThe Oncologist, 2005
- Myelodysplastic Syndromes — Coping with Ineffective HematopoiesisNew England Journal of Medicine, 2005
- JNK activation is a mediator of arsenic trioxide-induced apoptosis in acute promyelocytic leukemia cellsBlood, 2004
- Inhibition of NF-κB essentially contributes to arsenic-induced apoptosisBlood, 2003
- Randomized Controlled Trial of Azacitidine in Patients With the Myelodysplastic Syndrome: A Study of the Cancer and Leukemia Group BJournal of Clinical Oncology, 2002
- High-dose chemotherapy in high-risk myelodysplastic syndromeCancer, 2001
- Overexpression of tumor necrosis factor (TNF)-α and interferon (IFN)-γ by bone marrow cells from patients with myelodysplastic syndromesLeukemia, 1997
- Oxidative DNA damage in CD34+ myelodysplastic cells is associated with intracellular redox changes and elevated plasma tumour necrosis factor‐α concentrationBritish Journal of Haematology, 1997
- Proposals for the classification of the myelodysplastic syndromesBritish Journal of Haematology, 1982